Rznomics Receives FDA RMAT Designation for RZ-001 in Hepatocellular Carcinoma Treatment
Rznomics, a biopharmaceutical company specializing in RNA-based gene therapeutics, has been granted the Regenerative Medicine Advanced Therapy (RMAT) designation by the U.S. FDA for its investigational candidate RZ-001, aimed at treating hepatocellular carcinoma (HCC). This designation is based on promising Phase 1b/2a clinical data, including safety profiles and preliminary response rates. The RMAT designation is part of an FDA program designed to expedite the development and review of innovative therapies for serious conditions. RZ-001 utilizes a trans-splicing ribozyme-based RNA editing platform, offering a novel mechanism of action to enhance tumor selectivity and safety. 
